Woodland Hills, CA – According to filings with the U.S. Securities and Exchange Commission, Eyenuk is raising $26,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kaushal Solanki played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Eyenuk
Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers for risk assessment and disease surveillance. Eyenuks first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of diabetic retinopathy. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimers disease.

To learn more about Eyenuk, visit http://www.eyenuk.com/

Contact:
Kaushal Solanki, Chief Executive Officer
818-835-3585
https://www.linkedin.com/in/ksolanki/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved